Video

DIA 2023: Tamei Elliott Discusses DIA Educational Opportunities Improving Clinical Operations Staff

In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Tamei Elliott, Senior Manager, Scientific Programs, Drug Information Association, discusses DIA educational opportunities improving clinical operations staff on DE&I concerns.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Videos
Related Content
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
August 25th 2025

2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research

Don Tracy, Associate Editor
2025 DIA Global Annual Meeting: The Truth About AI Adoption Speed in Clinical Research
August 25th 2025

2025 DIA Global Annual Meeting: The Truth About AI Adoption Speed in Clinical Research

Don Tracy, Associate Editor
2025 DIA Global Annual Meeting: The Adoption of Artificial Intelligence and Machine Learning in Clinical Research
August 25th 2025

2025 DIA Global Annual Meeting: The Adoption of Artificial Intelligence and Machine Learning in Clinical Research

Andy Studna, Senior Editor
2025 DIA Global Annual Meeting Opening Keynote Panel: Global Collaboration to Derisk Innovation and Improve Patient Lives
August 25th 2025

2025 DIA Global Annual Meeting Opening Keynote Panel: Global Collaboration to Derisk Innovation and Improve Patient Lives

Andy Studna, Senior Editor
Credit: Crystal light | stock.adobe.com. Stomach cancer, gastric cancer, symptoms, stages, treatment, 3d illustration
August 25th 2025

Phase III MATTERHORN Trial Shows Imfinzi Combo Significantly Improves Event-Free Survival in Resectable Gastric and GEJ Cancers

Davy James
© iDoPixBox - © iDoPixBox - stock.adobe.com
August 25th 2025

Tecentriq and Zepzelca Combo Demonstrates Significant Survival Benefit in Phase III Study for Extensive-Stage Small Cell Lung Cancer

Andy Studna, Senior Editor
© 2025 MJH Life Sciences

All rights reserved.